European Journal of Haematology, EarlyView.ABSTRACT Objectives Teclistamab and talquetamab treatments are typically initiated in a hospital due to the potential risk of cytokine release syndrome. However, emerging data support the potential for outpatient administration (i.e., administration without overnight hospital admission).
Thomas Lund +12 more
wiley +1 more source
Bispecific Antibodies in Solid Tumors: Advances and Challenges. [PDF]
Int J Mol SciShan KS +7 more
europepmc +1 more source
Improved Pharmacokinetics of Recombinant Bispecific Antibody Molecules by Fusion to Human Serum Albumin [PDF]
, 2007 Dafne Müller +5 more
openalex +1 more source
Vaccination in Multiple Myeloma: Challenges and Strategies
European Journal of Haematology, EarlyView.ABSTRACT Background Multiple myeloma (MM) is a hematological malignancy characterized by profound immunosuppression resulting from both disease‐related mechanisms and treatment‐induced immune dysfunction. This compromised immune status markedly increases susceptibility to infections, a leading cause of morbidity and mortality in MM patients.
Enrica Antonia Martino +10 more
wiley +1 more source
Exploring T-cell bispecific antibodies in gynecologic malignancy. [PDF]
Gynecol Oncol RepO'Brien E, Mayer CM, Arend RC.
europepmc +1 more source
Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action [PDF]
, 2007 Zhengxing Qu +5 more
openalex +1 more source
Extracellular vesicles in multiple myeloma: pathogenesis and therapeutic application
The FEBS Journal, EarlyView.Multiple myeloma is characterised by the clonal proliferation of plasma cells in the bone marrow. Extracellular vesicles (EVs) are a key component of cell‐to‐cell communication within the bone marrow microenvironment, promoting tumour growth, bone remodelling, immune modulation, angiogenesis and therapeutic resistance.
Chloe Wylie +3 more
wiley +1 more source
Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma. [PDF]
Blood Cancer JGolmohammadi M +14 more
europepmc +1 more source
Construction of Optimized Bispecific Antibodies for Selective Activation of the Death Receptor CD95 [PDF]
, 2008 Tanja Herrmann +5 more
openalex +1 more source
Blood group O expression in normal tissues and tumors
The FEBS Journal, EarlyView.The H antigen (O blood group), the precursor to A and B blood groups, is expressed on human erythrocytes. Two novel monoclonal antibodies generated using sea lamprey immunization, Tn4‐31L and OmcFL3‐02, specifically detect the H antigen on glycan microarrays, glycoproteins, and human cells.
Ea Kristine Clarisse Tulin +11 more
wiley +1 more source